A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator’s Choice of Idelalisib Plus Rituxan or Bendamustine Plus Rituxan in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Principal Investigator
Mitul Gandhi, MDLocations
Fairfax Office
Gainesville Office
Arlington Office
Alexandria Office
Loudoun Office
Learn More About This Trial
Other Relevant Trials
A phase Ib/II open label dose confirmation, proof of concept study of siremadlin in combination with venetoclax plus azacitidine in unfit adult AML participants who responded sub-optimally to first-line venetoclax plus azacitidine treatment and in participants with newly diagnosed unfit AML presenting with high-risk clinical features (CHDM201I12201)
Principal Investigator
Mitul Gandhi, MDA Multicenter, Open-Label, First-in-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
